Incretin-like effects of small molecule trace amine-associated receptor 1 agonists

Molecular Metabolism

Volumn 5, Issue 1, 2016, Pages 47-56

  Raab, Susanne ^a   Wang, Haiyan ^a   Uhles, Sabine ^a   Cole, Nadine ^a   Alvarez Sanchez, Ruben ^a   Künnecke, Basil ^a   Ullmer, Christoph ^a   Matile, Hugues ^a   Bedoucha, Marc ^a   Norcross, Roger D ^a   Ottaway Parker, Nickki ^b   Perez Tilve, Diego ^b   Conde Knape, Karin ^a,d   Tschöp, Matthias H ^c   Hoener, Marius C ^a   Sewing, Sabine ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d JOHNSON AND JOHNSON   (United States)

Author keywords

Incretin hormones; Insulin secretion; Obesity; Pancreatic cell; Type 2 diabetes

Indexed keywords

REGULATOR PROTEIN; TRACE AMINE ASSOCIATED RECEPTOR 1; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; FOOD INTAKE; HUMAN; HUMAN CELL; HUMAN TISSUE; INSULIN RELEASE; INSULIN SENSITIVITY; MALE; METABOLIC REGULATION; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NORMAL HUMAN; OBESITY; PANCREAS ISLET; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; STOMACH EMPTYING; TISSUE DISTRIBUTION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84952873446     PISSN: 22128778     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmet.2015.09.015     Document Type: Article

References (39)

1. Lindemann L., Hoener M.C. A renaissance in trace amines inspired by a novel GPCR family. Trends in Pharmacological Sciences 2005, 26:274-281.
2. Lindemann L., Meyer C.A., Jeanneau K., Bradaia A., Ozmen L., Bluethmann H., et al. Trace amine-associated receptor 1 modulates dopaminergic activity. Journal of Pharmacology and Experimental Therapeutics 2008, 324:948-956.
3. Liberles S.D. Trace amine-associated receptors: ligands, neural circuits, and behaviors. Current Opinion in Neurobiology 2015, 34C:1-7.
4. Bunzow J.R., Sonders M.S., Arttamangkul S., Harrison L.M., Zhang G., Quigley D.I., et al. Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Molecular Pharmacology 2001, 60:1181-1188.
5. Borowsky B., Adham N., Jones K.A., Raddatz R., Artymyshyn R., Ogozalek K.L., et al. Trace amines: identification of a family of mammalian G protein-coupled receptors. Proceedings of the National Academy of Sciences U S A 2001, 98:8966-8971.
6. Lindemann L., Ebeling M., Kratochwil N.A., Bunzow J.R., Grandy D.K., Hoener M.C. Trace amine-associated receptors form structurally and functionally distinct subfamilies of novel G protein-coupled receptors. Genomics 2005, 85:372-385.
7. Revel F.G., Moreau J.L., Pouzet B., Mory R., Bradaia A., Buchy D., et al. A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight. Molecular Psychiatry 2013, 18:543-556.
8. Revel F.G., Moreau J.L., Gainetdinov R.R., Bradaia A., Sotnikova T.D., Mory R., et al. TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity. Proceedings of the National Academy of Sciences U S A 2011, 108:8485-8490.
9. Revel F.G., Moreau J.L., Gainetdinov R.R., Ferragud A., Velázquez-Sánchez C., Sotnikova T.D., et al. Trace amine-associated receptor 1 partial agonism reveals novel paradigm for neuropsychiatric therapeutics. Biological Psychiatry 2012, 72:934-942.
10. Regard J.B., Kataoka H., Cano D.A., Camerer E., Yin L., Zheng Y.W., et al. Probing cell type-specific functions of Gi in vivo identifies GPCR regulators of insulin secretion. Journal of Clinical Investigation 2007, 117:4034-4043.
11. Ito J., Ito M., Nambu H., Fujikawa T., Tanaka K., Iwaasa H., et al. Anatomical and histological profiling of orphan G-protein-coupled receptor expression in gastrointestinal tract of C57BL/6J mice. Cell and Tissue Research 2009, 338:257-269.
12. Larsson K., Hofstrom C., Lindskog C., Hansson M., Angelidou P., Hökfelt T., et al. Novel antigen design for the generation of antibodies to G-protein-coupled receptors. Journal of Immunological Methods 2011, 370:14-23.
13. Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256:495-497.
14. Sebokova E., Christ A.D., Wang H., Sewing S., Dong J.Z., Taylor J., et al. Taspoglutide, an analog of human glucagon-like peptide-1 with enhanced stability and in vivo potency. Endocrinology 2010, 151:2474-2482.
15. Scrocchi L.A., Brown T.J., MaClusky N., Brubaker P.L., Auerbach A.B., Joyner A.L., et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nature Medicine 1996, 2:1254-1258.
16. Osinski M.A., Seifert T.R., Cox B.F., Gintant G.A. An improved method of evaluation of drug-evoked changes in gastric emptying in mice. Journal of Pharmacological and Toxicological Methods 2002, 47:115-120.
17. Flock G., Holland D., Seino Y., Drucker D.J. GPR119 regulates murine glucose homeostasis through incretin receptor-dependent and independent mechanisms. Endocrinology 2011, 152:374-383.
18. Kunnecke B., Verry P., Benardeau A., von Kienlin M. Quantitative body composition analysis in awake mice and rats by magnetic resonance relaxometry. Obesity Research 2004, 12:1604-1615.
19. Tan C.P., Feng Y., Zhou Y.P., Eiermann G.J., Petrov A., Zhou C., et al. Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice. Diabetes 2008, 57:2211-2219.
20. Blase E., Taylor K., Gao H.Y., Wintle M., Fineman M. Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects. Journal of Clinical Pharmacology 2005, 45:570-577.
21. Chiellini G., Frascarelli S., Ghelardoni S., Carnicelli V., Tobias S.C., DeBarber A., et al. Cardiac effects of 3-iodothyronamine: a new aminergic system modulating cardiac function. Faseb Journal 2007, 21:1597-1608.
22. Regard J.B., Sato I.T., Coughlin S.R. Anatomical profiling of G protein-coupled receptor expression. Cell 2008, 135:561-571.
23. Berry M.D. Mammalian central nervous system trace amines. Pharmacologic amphetamines, physiologic neuromodulators. Journal of Neurochemistry 2004, 90:257-271.
24. Burchett S.A., Hicks T.P. The mysterious trace amines: protean neuromodulators of synaptic transmission in mammalian brain. Progress in Neurobiology 2006, 79:223-246.
25. Scanlan T.S., Suchland K.L., Hart M.E., Chiellini G., Huang Y., Kruzich P.J., et al. 3-Iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone. Nature Medicine 2004, 10:638-642.
26. Dinter J., Mühlhaus J., Jacobi S.F., Wienchol C.L., Cöster M., Meister J., et al. 3-Iodothyronamine differentially modulates alpha-2A-adrenergic receptor-mediated signaling. Journal of Molecular Endocrinology 2015, 54:205-216.
27. Nauck M.A., Niedereichholz U., Ettler R., Holst J.J., Orskov C., Ritzel R., et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. American Journal of Physiology 1997, 273:E981-E988.
28. Little T.J., Pilichiewicz A.N., Russo A., Phillips L., Jones K.L., Nauck M.A., et al. Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses. Journal of Clinical Endocrinology & Metabolism 2006, 91:1916-1923.
29. Friedlander R.S., Moss C.E., Mace J., Parker H.E., Tolhurst G., Habib A.M., et al. Role of phosphodiesterase and adenylate cyclase isozymes in murine colonic glucagon-like peptide 1 secreting cells. British Journal of Pharmacology 2011, 163:261-271.
30. Parker H.E., Wallis K., le Roux C.W., Wong K.Y., Reimann F., Gribble F.M. Molecular mechanisms underlying bile acid-stimulated glucagon-like peptide-1 secretion. British Journal of Pharmacology 2012, 165:414-423.
31. Furman B., Ong W.K., Pyne N.J. Cyclic AMP signaling in pancreatic islets. Advances in Experimental Medicine and Biology 2010, 654:281-304.
32. Adriaenssens A., Yee Hong Lam B., Billing L., Skeffington K., Sewing S., Reimann F., et al. A transcriptome-led exploration of molecular mechanisms regulating somatostatin-producing D-cells in the gastric epithelium. Endocrinology 2015, en20151301.
33. Small C.J., Bloom S.R. Gut hormones as peripheral anti obesity targets. CNS & Neurological Disorders-Drug Targets 2004, 3:379-388.
34. Wynne K., Bloom S.R. The role of oxyntomodulin and peptide tyrosine-tyrosine (PYY) in appetite control. Nature Clinical Practice Endocrinology & Metabolism 2006, 2:612-620.
35. Talsania T., Anini Y., Siu S., Drucker D.J., Brubaker P.L. Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice. Endocrinology 2005, 146:3748-3756.
36. Campbell J.E., Drucker D.J. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metabolism 2013, 17:819-837.
37. Dunphy J.L., Taylor R.G., Fuller P.J. Tissue distribution of rat glucagon receptor and GLP-1 receptor gene expression. Molecular and Cellular Endocrinology 1998, 141:179-186.
38. Spano G., Russo P., Lonvaud-Funel A., Lucas P., Alexandre H., Grandvalet C., et al. Biogenic amines in fermented foods. European Journal of Clinical Nutrition 2010, 3(64 Suppl.):S95-S100.
39. Pessione E. Lactic acid bacteria contribution to gut microbiota complexity: lights and shadows. Frontiers in Cellular and Infection Microbiology 2012, 2:86.